You are here

Allscripts to release third-quarter 2018 financial results November 1

CHICAGO, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Allscripts Healthcare Solutions, Inc. (Nasdaq:MDRX) will report its financial results for the three months ended September 30, 2018, after the close of stock market hours on Thursday, November 1, 2018. Allscripts management plans to host a conference call and webcast to discuss the company's earnings and other information at 4:30 p.m. Eastern Time that same day.

Third-Quarter 2018 Financial Results Call Details

The Allscripts earnings announcement will be distributed immediately after the close of regular stock market hours on November 1, 2018. The announcement will also be available at Allscripts investor relations website.

To listen to the conference call, participants may log onto the Allscripts Investor Relations website. Participants also may access the conference call by dialing (877) 269-7756 or 201-689-7817 and requesting Conference ID #13683970.

A replay of the call will be available approximately two hours after the conclusion of the call, for a period of four weeks, on the Allscripts investor relations website or by calling (877) 660-6853 or (201) 612-7415 - Conference ID #13683970.

About Allscripts
Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2018 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.
Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

For more information contact:

Investors:
Stephen Shulstein
312-386-6735
Stephen.Shulstein@allscripts.com

Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@allscripts.com

Thursday, October 11, 2018 - 08:01

More Headlines

Resorbable Dextenza is the First Intracanalicular Insert for Drug Delivery
Patients with MS Suffered Stroke, Blood Vessel Tearing in Head and Neck After Receiving Drug
First Biosimilar For Adults With CD20-Positive, B-Cell Non-Hodgkin’s Lymphoma
Life-Threatening Side Effect of Drug for Acute Myeloid Leukemia
First Drug for Rare Autoimmune Disorder That Affects Nerve, Muscles Connection
Hope For Patients With Highly Aggressive Form of AML
Oncology Therapy for Adult and Pediatric Tumors With a Neurotrophic Receptor Tyrosine Kinase (NTRK) Gene Fusion
First Hedgehog Pathway Inhibitor Approved for AML in Adults Aged 75 and Older
Gene Therapy Granted Regenerative Medicine, Fast Track Designations